ad

Poly Medicure Q1 FY27 Results: Revenue Rs 525 Cr, PAT Rs 83 Cr and Key Highlights

Poly Medicure Q1 FY27 results declared August 7, 2026. Revenue Rs 525 Cr (+30.30% YoY). PAT Rs 83 Cr (-8.76% YoY). CMP Rs 1693.8 (-0.91%).


10 Aug 202612:17 pm

Poly Medicure Q1 FY27 Results: Revenue Rs 525 Cr, PAT Rs 83 Cr and Key Highlights

Poly Medicure Q1 FY27 results were announced on August 7, 2026, consolidated. Revenue grew +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. The broader BSE Healthcare index reflected mixed sentiment during the quarter.

Operating profit stood at Rs 88 Cr (+7.20% YoY). PAT came in at Rs 83 Cr (-8.76% YoY), offering a comprehensive view of how Poly Medicure is navigating the current medical devices environment.

Click Here – Get Free Investment Predictions

Poly Medicure Q1 FY27 Financial Highlights

Metric Q1 FY27 (Rs Cr) Q1 FY26 (Rs Cr) YoY Change
Poly Medicure Revenue 525 403 +30.30%
Operating Profit 88 82 +7.20%
Net Profit (PAT) 83 91 -8.76%
Reporting Basis Consolidated

Poly Medicure Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Poly Medicure Q1 FY27 results reflect modest fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 525 Cr for the April to June 2026 quarter.

Operating profit expanded +7.20% YoY to Rs 88 Cr. This indicates improving cost efficiency and better product mix.

PAT of Rs 83 Cr marks a -8.76% YoY movement in Poly Medicure Q1 FY27 results. Investors monitoring Poly Medicure Q1 FY27 results will note this as a key FY27 performance milestone.

Key Business Factors in Poly Medicure Q1 FY27 Results

Revenue Expansion Driving Top-Line Growth

Poly Medicure Q1 FY27 results show top-line strength with revenue growing +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. Order execution momentum and market share gains in the Medical Devices segment fuelled this expansion.

Operating Leverage and Margin Improvement

Operating profit in Poly Medicure Q1 FY27 results improved +7.20% YoY to Rs 88 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.

PAT Performance and Profitability Trend

Net profit (PAT) in Poly Medicure Q1 FY27 results stood at Rs 83 Cr ((-8.76% YoY)). Near-term PAT moderation is being managed through cost optimisation and revenue diversification.

Dividend Details

No dividend was announced alongside Poly Medicure Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.

FY27 Outlook for Poly Medicure

Following Poly Medicure Q1 FY27 results, management has reiterated a recovery-focused strategy targeting operational efficiencies, cost rationalisation, and revenue diversification. The pace of recovery in the medical devices segment will be a key monitorable for investors tracking Poly Medicure Q1 FY27 results. Consult a SEBI-registered financial advisor before making decisions.

Poly Medicure Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Poly Medicure live price and get daily stock recommendations.

Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026, reflecting investor sentiment on the Poly Medicure Q1 FY27 results and near-term sector outlook. The CMP of Rs 1693.8 on the results date reflects broader market and sector sentiment in the medical devices space.

Key Risks for Poly Medicure

Sector-Specific Risks

Regulatory approvals for new products and competition from imported devices.

Valuation and Earnings Risk

Sustained earnings pressure may delay re-rating; near-term earnings visibility remains limited.

Operational and Financial Risk

Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.

Conclusion

Poly Medicure Q1 FY27 results reflect modest performance with revenue at Rs 525 Cr and PAT at Rs 83 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Poly Medicure Q1 FY27 Results

When were Poly Medicure Q1 FY27 results declared?

Ans. Poly Medicure Q1 FY27 results were declared on August 7, 2026, covering the April to June 2026 quarter on a Consolidated basis.

What was Poly Medicure revenue in Q1 FY27?

Ans. Poly Medicure Q1 FY27 results show revenue of Rs 525 Cr, +30.30% compared to Rs 403 Cr in Q1 FY26.

What was Poly Medicure PAT in Q1 FY27?

Ans. Net profit in Poly Medicure Q1 FY27 results was Rs 83 Cr, -8.76% year-on-year.

Did Poly Medicure declare a dividend in Q1 FY27?

Ans. No dividend was announced alongside Poly Medicure Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.

What is the FY27 outlook for Poly Medicure?

Ans. Management has guided operational restructuring and return to profitability for FY27. Sector trends and order visibility will be key monitorables for investors.

How did Poly Medicure stock react to Q1 FY27 results?

Ans. Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026 following the Poly Medicure Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down